Background: Several case series of patients with Tolosa-Hunt syndrome have been described in the literature; however, few studies have focused on the cerebrospinal fluid (CSF) characteristics. This study aimed to analyse the CSF characteristics of patients with Tolosa-Hunt syndrome. Methods: Fifty-five patients who fulfilled the 3rd Edition of the International Classification of Headache Disorders diagnostic criteria for Tolosa-Hunt syndrome were included in this study. We retrospectively analysed data on CSF parameters, imaging findings, and clinical characteristics of these patients. Results: Oligoclonal bands (OBs) were detected in the CSF of 13 (13/44, 29.5%) patients. The sex ratio was balanced. The mean age at onset of Tolosa-Hunt syndrome was 46.9 ± 10.23 (range 22–72) years. Eight (8/13, 61.5%) patients had multiple cranial nerve palsies. Lesions limited to the cavernous sinus were found on magnetic resonance imaging in 7 (7/13, 53.8%) patients. OBs were significantly detected more frequently in patients whose samples were evaluated less than 30 days after the onset of this diseases (p = 0.026); however, there were no significant differences in the protein level (p = 0.360) and IgG synthesis rate (p = 0.614). Conclusions: The detection of OBs in the CSF of patients with Tolosa-Hunt syndrome was not rare. It would be interesting to follow-up patients with OBs to determine whether they eventually developed an otherwise more specific inflammatory diagnosis.

1.
Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition
.
Cephalalgia
.
2018
;
38
(
1
):
1
211
.
2.
Hung
CH
,
Chang
KH
,
Chen
YL
,
Wu
YM
,
Lai
CL
,
Chang
HS
,
Clinical and radiological findings suggesting disorders other than Tolosa-Hunt syndrome among ophthalmoplegic patients: a retrospective analysis
.
Headache
.
2015
;
55
(
2
):
252
64
.
3.
Hao
R
,
He
Y
,
Zhang
H
,
Zhang
W
,
Li
X
,
Ke
Y
.
The evaluation of ICHD-3 beta diagnostic criteria for Tolosa-Hunt syndrome: a study of 22 cases of Tolosa-Hunt syndrome
.
Neurol Sci
.
2015
;
36
(
6
):
899
905
.
4.
Zhang
X
,
Zhang
W
,
Liu
R
,
Dong
Z
,
Yu
S
.
Factors that influence Tolosa-Hunt syndrome and the short-term response to steroid pulse treatment
.
J Neurol Sci
.
2014
;
341
(
1–2
):
13
6
. .
5.
La Mantia
L
,
Curone
M
,
Rapoport
AM
,
Bussone
G
;
International Headache Society
.
Tolosa-Hunt syndrome: critical literature review based on IHS 2004 criteria
.
Cephalalgia
.
2006
;
26
(
7
):
772
81
.
6.
Evers
S
.
Facial pain: overlapping syndromes
.
Cephalalgia
.
2017
;
37
(
7
):
705
13
. .
7.
Akpınar
ÇA
,
Özbenli
T
,
Doğru
H
,
İncesu
L
.
Tolosa-Hunt syndrome -cranial neuroimaging findings
.
Arch Neurol Psychiatry
.
2017
;
54
:
251
4
.
8.
Jain
R
,
Sawhney
S
,
Koul
RL
,
Chand
P
.
Tolosa-Hunt syndrome: MRI appearances
.
J Med Imaging Radiat Oncol
.
2008
;
52
(
5
):
447
51
.
9.
İlgen Uslu
F
,
Özkan
M
.
Painful ophthalmoplegia: a case report and literature review
.
Agri
.
2015
;
27
(
4
):
219
23
.
10.
Tolosa
E
.
Periarteritic lesions of the carotid siphon with the clinical features of a carotid infraclinoidal aneurysm
.
J Neurol Neurosurg Psychiatry
.
1954
;
17
(
4
):
300
2
. .
11.
Hunt
WE
,
Meagher
JN
,
Lefever
HE
,
Zeman
W
.
Painful opthalmoplegia: its relation to indolent inflammation of the carvernous sinus
.
Neurology
.
1961
;
11
:
56
62
.
12.
Adeel
A
,
Shahzaib
N
,
Muhammad
SP
,
Ali
R
.
Tolosa-Hunt syndrome: an arcane pathology of cavernous venous sinus
.
BMJ Case Rep
.
2015
;
2015
:
bcr2015210646
.
13.
Zurawski
J
,
Akhondi
H
.
Tolosa-Hunt syndrome: a rare cause of headache and ophthalmoplegia
.
Lancet
.
2013
;
382
(
9895
):
912
. .
14.
Zhang
X
,
Zhou
Z
,
Steiner
TJ
,
Zhang
W
,
Liu
R
,
Dong
Z
,
Validation of ICHD-3 beta diagnostic criteria for 13.7 Tolosa-Hunt syndrome: analysis of 77 cases of painful ophthalmoplegia
.
Cephalalgia
.
2014
;
34
(
8
):
624
32
.
15.
Jarholm
JA
,
Faiz
KW
,
Nysted
T
,
Zarnovicky
S
,
Kristoffersen
ES
.
Orbital pain, ophthalmoplegia, and oligoclonal bands in the cerebrospinal fluid: a case report of Tolosa-Hunt syndrome
.
Headache
.
2018
;
58
(
5
):
758
60
.
16.
Deisenhammer
F
,
Zetterberg
H
,
Fitzner
B
,
Zettl
UK
.
The cerebrospinal fluid in multiple sclerosis
.
Front Immunol
.
2019
;
10
:
726
. .
17.
Reiber
H
,
Felgenhauer
K
.
Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system
.
Clin Chim Acta
.
1987
;
163
(
3
):
319
28
. .
18.
Fischer
C
,
Arneth
B
,
Koehler
J
,
Lotz
J
,
Lackner
KJ
.
Kappa free light chains in cerebrospinal fluid as markers of intrathecal immunoglobulin synthesis
.
Clin Chem
.
2004
;
50
(
10
):
1809
13
. .
19.
Petzold
A
.
Intrathecal oligoclonal IgG synthesis in multiple sclerosis
.
J Neuroimmunol
.
2013
;
262
(
1–2
):
1
10
. .
20.
Mullen
E
,
Green
M
,
Hersh
E
,
Iloreta
AM
,
Bederson
J
,
Shrivastava
R
.
Tolosa-Hunt syndrome: appraising the ICHD-3 beta diagnostic criteria
.
Cephalalgia
.
2018
;
38
(
10
):
1696
700
.
21.
Yang
Q
,
Sun
L
,
Wang
Q
,
Wang
J
,
Meng
C
,
Chang
Q
,
Primary optic neuropathy in Behcet’s syndrome
.
Mult Scler
.
2019
;
25
(
8
):
1132
40
.
22.
Amrutkar
C
,
Burton
EV
.
Tolosa-Hunt syndrome
.
StatPearls [Internet]
.
Treasure Island, FL
:
StatPearls Publishing
;
2022
.
23.
Yang
Y
,
Lai
C
,
Yan
F
,
Wang
J
.
Clinical significance of MRI contrast enhancement of the oculomotor nerve in ischemic isolated oculomotor nerve palsy
.
J Clin Neurol
.
2020
;
16
(
4
):
653
8
. .
24.
Shazly
TA
,
Mitchell
EB
,
Bonhomme
GR
,
Schuman
JS
.
Lymphoma of the orbit masquerading as Tolosa-Hunt syndrome
.
BMC Ophthalmol
.
2015
;
15
:
51
. .
25.
Thompson
AJ
,
Banwell
BL
,
Barkhof
F
,
Carroll
WM
,
Coetzee
T
,
Comi
G
,
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
.
Lancet Neurol
.
2018
;
17
(
2
):
162
73
.
26.
Wingerchuk
DM
,
Banwell
B
,
Bennett
JL
,
Cabre
P
,
Carroll
W
,
Chitnis
T
,
International consensus diagnostic criteria for neuromyelitis optica spectrum disoerders
.
Neurology
.
2015
;
85
(
2
):
177
89
.
27.
Lo Sasso
B
,
Agnello
L
,
Bivona
G
,
Bellia
C
,
Ciaccio
M
.
Cerebrospinal fluid analysis in multiple sclerosis diagnosis: an update
.
Medicina
.
2019
;
55
(
6
):
245
. .
28.
Matute-Blanch
C
,
Montalban
X
,
Comabella
M
.
Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system
.
Handb Clin Neurol
.
2017
;
146
:
67
84
. .
29.
Uzawa
A
,
Mori
M
,
Masuda
S
,
Kuwabara
S
.
Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica
.
Arch Neurol
.
2011
;
68
(
7
):
913
7
. .
30.
Tatomir
A
,
Talpos-Caia
A
,
Anselmo
F
,
Kruszewski
AM
,
Boodhoo
D
,
Rus
V
,
The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis
.
Immunol Res
.
2017
;
65
(
6
):
1103
9
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.